Search
Clinician Ordering Portal
Scientific evidence
Atypical melanocytic proliferation on sensitive preauricular check
Jun 2023
Histopathological assessment of a melanocytic lesion on the check could not definitively rule out melanoma leading to the use of GEP prior to determining surgical management.
Abnormally pigmented lesion with uncertain malignant potential
Jun 2023
With benign GEP results, dermatopathologist adjusts diagnosis to a benign neoplasm and patient avoids re-excision.
Clinical use of a diagnostic gene expression signature for melanocytic neoplasms
May 2021
Patients managed in accordance with a benign 23-GEP result, including forgoing re-excision, reported no adverse events during the follow-up period.
Publication: Cutis
Clinical validity of a gene expression signature in diagnostically uncertain neoplasms
Jun 2020
A retrospective study demonstrating high diagnostic accuracy of the 23-GEP in diagnostically uncertain cases when evaluated against clinical outcomes.
Publication: Personalized Medicine
Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions
Apr 2019
Clinical validation study of the 23-GEP in lesions with clinical outcomes and follow-up data.
Publication: Human Pathology
Gene expression signature as an ancillary method in the diagnosis of desmoplastic melanoma
Dec 2017
Assessment of the sensitivity and specificity of 23-GEP in melanocytic lesions with a desmoplastic component.
Publication: Human Pathology
Diagnostic distinction of malignant melanoma and benign nevi by a gene expression signature and correlation to clinical outcomes
Jul 2017
Large outcomes-proven validation cohort establishes high levels of sensitivity and specificity in melanomas with proven distant metastasis and nevi with 6+ years of event free follow-up.
Publication: Cancer Epidemiology, Biomarkers, and Prevention
The influence of a gene expression signature on the treatment of diagnostically challenging melanocytic lesions
Jan 2017
MyPath Melanoma guides dermatologists in treatment decisions leading to a 72% reduction in re-excisions when the GEP result is benign.
Publication: Personalized Medicine
An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi
Oct 2016
Establishes the performance of the gene expression signature in prospectively submitted cases with triple concordant diagnosis.
Publication: Cancer
The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists
Oct 2016
Definitive diagnoses by dermatopathologists in challenging melanocytic lesions increased by 57% by incorporating the results of 23-GEP.
Publication: Medicine
Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma
Mar 2015
Initial development and validation of the 23-GEP establishing a high level of sensitivity and specificity in a broad range of histopathological subtypes.
Publication: Journal of Cutaneous Pathology
Analytical validation of a melanoma diagnostic gene signature using formalin-fixed paraffin-embedded melanocytic lesions
Mar 2015
Analytical validation study to establish precision, dynamic range, RNA yield, reproducibility, and melanin inhibition.
Publication: Biomarkers in Medicine